Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BPU6
UPID:
DPYL5_HUMAN
Alternative names:
CRMP3-associated molecule; Collapsin response mediator protein 5; UNC33-like phosphoprotein 6
Alternative UPACC:
Q9BPU6; Q8TCL6; Q9NQC4; Q9NRY9
Background:
Dihydropyrimidinase-related protein 5, also known as CRMP3-associated molecule, Collapsin response mediator protein 5, and UNC33-like phosphoprotein 6, plays a crucial role in the negative regulation of dendrite outgrowth. This protein, identified by the accession number Q9BPU6, is pivotal in neuronal development and function.
Therapeutic significance:
Linked to Ritscher-Schinzel syndrome 4, a condition marked by cerebellar brain anomalies, developmental delays, and congenital heart defects, dihydropyrimidinase-related protein 5's study offers insights into potential therapeutic interventions for this genetic disorder.